Open AccessComparison of two kits of anti-infliximab antibodies plasmatic measurement
Author(s) -
Rim Charfi,
I. Mahmoud,
Fatma Ben Salem,
Myriam Moalla,
S. Bouden,
Imen Sfar,
O. Saidane,
Anis Klouz,
Riadh Daghfous,
Yousr Gorgi,
L. Abdelmoula,
Sameh Trabelsi
Publication year - 2019
Publication title -
annales de biologie clinique
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.167
H-Index - 27
eISSN - 1950-6112
pISSN - 0003-3898
DOI - 10.1684/abc.2019.1454
Subject(s) - infliximab , antibody , medicine , immunology , tumor necrosis factor alpha
Infliximab (IFX) is a chimeric monoclonal antibody which has proven its efficacy in the treatment of inflammatory diseases. However, its efficacy can be limited by the development of anti-IFX antibodies (ATI) resulting in a therapeutic failure of IFX. ATI plasmatic monitoring is then indicated to optimize IFX treatment. The aim of this study was to validate an ELISA (enzyme linked immuno sorbent assay) method of ATI plasmatic monitoring.